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Crm1 knockdown by specific small interfering RNA reduces cell proliferation and
induces apoptosis in head and neck cancer cell lines
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Abstract: Head and neck squamous cell carcinoma (HNSCC) is the most common and most aggressive type of head and neck cancer.
Current approaches for the treatment of HNSCC are not sufficient to increase the patient survival or to reduce the high recurrence
rate. Consequently, there is a need to explore the molecular characteristics of this cancer in order to discover potential therapeutic
target molecules. The overexpression of chromosome region maintenance 1 (Crm1), responsible for the transport of different classes of
macromolecules from the nuclear membrane to the cytoplasm, in various cancer cells has made it an attractive target molecule in cancer
research. It has been reported that transcription factors, which are the target cargo proteins of Crm1, have critical roles in regulating
intracellular processes via their expression levels and functions, which in turn are regulated by the cell cycle and signaling proteins.
Previous findings show that head and neck cancer cells overexpress Crm1 and that these cells become highly dependent on Crm1
function. The results of this study show that after decreasing Crm1 expression levels in HNSCC cells through either treatment with
specific Crm1 RNA interference (siRNA) or the selective Crm1 inhibitor leptomycin B (LMB), cell viability, proliferation, migration,
and wound-healing abilities decreased, suppressing tumorigenic properties through the induction of apoptosis. Crm1 is a powerful
diagnostic biomarker because of its central role in cancerogenesis, and it has a high potential for the development of targeted Crm1
molecules or synthetic agents, such as LMB, as well as for the improvement of the clinical features in head and neck cancer.
Key words: Head and neck cancer, chromosome region maintenance 1, metastasis, RNA interference, leptomycin B

1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is the
sixth most common cancer type and represents the third
most common cause of cancer-related deaths worldwide
(Stell et al., 1989; Jemal et al., 2009). It constitutes 4% of all
cancer cases, resulting in approximately 650,000 new cases
and 400,000 deaths annually (Mao et al., 2004; Siegel et al.,
2014). In most cases of HNSCC, only 51% of short-term
malignancies and only 10.5% of long-term malignancies
could be detected even with advanced investigations. Fiveyear survival rates are 51% in short-term malignancies and
28% in long-term malignancies (Jemal et al., 2009).
The underlying mechanism of HNSCC invasion and
metastasis is a multistep process characterized by multiple
genetic and molecular changes (Wilken et al., 2011).
However, not all of the underlying molecular mechanisms
of HNSCC pathology are clear. Additionally, despite the
standard therapies, including radiation, surgery, and/or
chemotherapy, there has been no significant change in the
survival rate within the last 20–30 years, and the mortality
* Correspondence: sozdas@adanabtu.edu.tr
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rate for HNSCC is still high (Jemal et al., 2009). Therefore,
it is very important to investigate new candidate molecules
for the diagnosis, follow-up, and control of HNSCC.
Moreover, the investigation of potential target molecules
that may be responsible for the HNSCC pathogenesis is
crucial for the development of new clinical therapeutic
approaches.
Chromosome region maintenance 1 (Crm1), a member
of the cytoplasm-nucleus transport receptor family known
as the karyopherins, is an important nuclear export protein
in mammals that facilitates the transport of various classes
of RNAs, proteins, and other macromolecules from the
nuclear membrane to the cytoplasm, and it helps maintain
their appropriate subcellular localization (Kudo et al.,
1997; Nguyen et al., 2012; Turner et al., 2012). Crm1 has a
broad range of substrates and recognizes numerous cargo
proteins, which are rich in nuclear export signal (NES)
sequences, including tumor suppressor proteins such
as p53, p27, and p21. These tumor suppressor proteins
carry NES sequences rich in leucine amino acids and
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hydrophobic residues (Fukuda et al., 1997; Henderson et
al., 2000; Mariano et al., 2006; Chan et al., 2010; van der
Watt et al., 2011; Brodie et al., 2012; Santiago et al., 2013;
Fung et al., 2014). Furthermore, transcription factors that
are the target cargo proteins of Crm1 have critical roles in
the regulation of intracellular processes via their expression
levels and functions, which are regulated by the cell cycle
and signaling proteins (Henderson et al., 2000; Mariano et
al., 2006; Chan et al., 2010; van der Watt et al., 2011; Brodie
et al., 2012; Santiago et al., 2013). The deregulation of Crm1
expression, which is dependent on the cell cycle, results in
the loss of cellular proliferation control through various
intracellular pathways (Ishizawa et al., 2015). Recent
studies on various cancer types have reported an increase
in the expression level of Crm1 compared with healthy
tissue, and this increase has been found to be associated
with metastasis, histological grading, increased tumor size,
and a decreased general survival rate (Noske et al., 2008;
Shen et al., 2009; van der Watt et al., 2009, 2014; Yao et al.,
2009; Zhou et al., 2013; Tai et al., 2014; Yang et al., 2014; Liu
et al., 2016). The increased expression level of Crm1 has
also been shown to play a key role in carcinogenesis, and it
was observed that in retrovirus-mediated small interfering
RNA (siRNA)-introduced Crm1 knockdown cancer lines,
the proliferation and migration abilities of the cells were
suppressed and apoptosis was induced (van der Watt et al.,
2009, 2014; Yang et al., 2014). Therefore, Crm1, a nuclear
export molecule, has become a significantly promising
target for the treatment of cancer (Yashiroda et al., 2003;
Turner et al., 2011). Leptomycin B (LMB) appeared as an
efficient inhibitor molecule that blocks the function of the
Crm1 protein. It has been reported that LMB irreversibly
binds to the residue Cys528 in the ligand-binding domain
of Crm1 and selectively inhibits this protein (Wolff et al.,
1997; Kudo et al., 1999). Preclinical studies using LMB as
an anticancer agent are ongoing (Newlands et al., 1996).
Apoptotic pathways in cancer cells are activated by the

specific Crm1-inhibitory function of LMB (Noske et al.,
2008; van der Watt et al., 2009, 2014; Yang et al., 2014).
The aim of this study was to investigate the potential
role of Crm1 in head and neck cancer pathology, as well
as to shed light on its potential as a therapeutic target. The
effects of specific Crm1 knockdown and inhibition on cell
proliferation, migration, and cellular apoptotic response in
head neck cancer cells were investigated.
2. Materials and methods
2.1. Cell cultures
The following HNSCC cell lines were used for all
experiments: UT-SCC-16A, UT-SCC-16B, UT-SCC-60A,
UT-SCC-60B, UT-SCC-74, and UT-SCC-74B were kindly
provided by Prof Dr Reidar Grenman (Department of
Otorhinolaryngology-Head and Neck Surgery and Medical
Biochemistry and Molecular Biology, Turku University and
Turku University Central Hospital, Turku, Finland). All of
them were originally established head and neck squamous
cell carcinoma primary tumors (A series) and their
associated metastatic tumors (B series). Characteristics
of the cell lines are summarized in the Table. Cells were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM)/High Glucose (Cat# SH30243.01; HyClone, GE
Healthcare, South Logan, UT, USA), supplemented with
penicillin (100 U/mL), streptomycin (100 µg/mL) (Cat#
SV30010; HyClone, GE Healthcare), 10% fetal bovine
serum (FBS) (Cat# SV30160.03; HyClone, GE Healthcare),
0.8% L-glutamine (Cat# SH30034.01; HyClone, GE
Healthcare), and 0.01% Plasmocin (ant-mpt; InvivoGen,
San Diego, CA, USA). Cell lines were cultured at 37 °C in
a humidified atmosphere of 5% CO2.
2.2. LMB treatment
We used LMB (Cat# ab120501; Abcam, Cambridge, MA,
USA) to test the effect of Crm1 inhibition on the apoptotic
status, proliferation, and migration capability of head and
neck cancer cells. LMB was stored as a 10.2 µM stock

Table. Clinicopathological characteristics of the HNSCC cell lines.
Accession ID

Cell line name

Sex of
cell

Age

Primary tumor
origin

TNM
classification

Specimen
site

Histological
grade

CVCL_7812

UT-SCC-16A

F

77

SCC, tongue

T3N0M0

Tongue

G3

CVCL_7813

UT-SCC-16B

F

77

SCC, tongue

T3N0M0

Neck

G3

CVCL_A089

UT-SCC-60A

M

59

Tonsil

T4N1M0

Tonsil

G1

CVCL_A090

UT-SCC-60B

M

59

Tonsil

T4N1M0

Neck

G1

CVCL_7779

UT-SCC-74A

M

31

SCC, tongue

T3N1M0

Tongue

G1–G2

CVCL_7780

UT-SCC-74B

M

31

SCC, tongue

rN2

Neck

G2

HNSCC: Head and neck cancer, M: male, F: female, TNM: TNM classification (T: tumor, N: lymph node involvement, M: distance
metastases), SCC: squamous cell carcinoma.
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in ethanol. The cells were suspended in culture plates,
preincubated at 37 °C overnight, and then treated for 48
h with different concentrations of LMB (0, 0.5, 1, 10, 20,
and 40 nM).
2.3. RNA interference
All siRNAs were synthesized by GE Healthcare
Dharmacon (Lafayette, CO, USA). For the inhibition of
Crm1 gene expression siRNAs, ON-TARGETplus Human
CRM1 siRNA-SMARTpool was used (Cat# L-003030-000005; GE Healthcare Dharmacon). siRNA consisting of a
scrambled sequence from the ON-TARGETplus Human
Non-targeting Control Pool (Cat# D-001810-10-05;
GE Healthcare Dharmacon) was used as a nonsilencing
control and GAPDH from the ON-TARGETplus Human
GAPDH Control Pool (Cat# D-001830-10-05; GE
Healthcare Dharmacon) was used as a control. Cells were
seeded in complete media (without antibiotics) the day
before the experiment (1–1.2 × 105 cells/well). Cell lines
were transiently transfected with 25 nM siRNA into the
cell lines using DharmaFECT-1 reagent (0.2 mL) (Cat#
T-2001-01; GE Healthcare Dharmacon) according to the
manufacturer’s protocol.
2.4. Quantitative real‑time reverse transcription‑PCR
RNA was isolated from the cell lines using TRIzol
reagent (Cat# 15596026; Invitrogen, Rockville, MD,
USA) and transcribed into cDNA using the Transcriptor
High Fidelity cDNA Synthesis Kit (Cat# 05091284001;
Roche Applied Science, Penzberg, Germany). The assays
were performed in accordance with the manufacturer’s
instructions. Quantitative real‑time PCR was performed
using the SYBR Green qPCR kit (Cat# 04887352001;
Roche Applied Science) using the following primer
pairs: Crm1 (F 5’ GGGAAAACTGAAACCCACCT 3’
and R 5’ CTGAAATCAAGCAGCTGACG 3’), betaactin (F 5’ TTCCTGGGCATGGAGTCCT 3’ and R 5’
AGGAGGAGCAATGATCTTGATC 3’), and GAPDH
(F 5’ CAAGGTCATCCATGACAACTTTG 3’ and R 5’
GTCCACCACCCTGTTGCTGTAG 3’), where beta-actin
and GAPDH were used to normalize for Crm1 expression.
For qRT-PCR, the Rotor-Gene Q 5plex HRM Platform
(QIAGEN, Hilden, Germany) was used and the data
were analyzed using Rotor Gene Q Software 1.2 software
(QIAGEN).
2.5. Western blot analysis
Cells in culture grown to 80% confluency were washed
with precooled (4 °C) PBS (Cat# 51226; AccuGENE,
Lonza, Walkersville, MD, USA) 3 times and lysed in
radioimmunoprecipitation assay (RIPA) buffer (Cat#
89900; Thermo Scientific, Vernon Hills, IL, USA). Total
proteins in the supernatant were collected. The protein
concentrations were quantified by Bradford assay and 20
µg of total protein was used for western blot analysis. First
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30 µL of each protein sample was mixed with 10 µL of 4X
SDS sample buffer and separated by electrophoresis in an
SDS-PAGE gel and transferred to polyvinylidene difluoride
(PVDF) Hybond ECL nitrocellulose membranes (Cat#
RPN2020D; GE Healthcare UK Limited, Amersham, UK).
For western blot analyses, the membranes were
incubated at 4 °C overnight with primary antibodies
against Crm1 (1/1000, Cat# ab24189; Abcam) and β-actin
(1/20000, Cat#sc-47778; Santa Cruz Biotechnology, Inc.,
Dallas, TX, USA). Then the membranes were subsequently
incubated with horseradish peroxidase-linked secondary
antibody anti-Crm1 rabbit IgG (1/3000, Cat# ab9705;
Abcam) and anti-β-actin mouse IgG (1/2500, Cat #7076P2;
Cell Signaling Technology, Danvers, MA, USA) at 37 °C for
1 h with shaking, and the bound proteins were visualized
by ECL substrate (Cat# 1705060; Bio-Rad, Hercules, CA,
USA) using the ChemiDoc MP Imaging System (BioRad). The relative intensities were evaluated with ImageJ
software (https://imagej.net/Welcome).
2.6. Immunofluorescence analysis
The cells were first counted and 3 × 105 cells were seeded
onto 13-mm coverslips (Nunc Thermanox, Cat# 174950;
Thermo Scientific) for 24 h. At 48 h after transfection or
inhibition, the medium was removed, and then cells were
fixed for 10 min with 4% formaldehyde (Cat# F8775;
Sigma-Aldrich, St. Louis, MO, USA) in PBS at room
temperature. Following 2 washes with PBS and fixing,
cells were permeabilized in 0.5% Triton X-100 (Cat#
11332481001; Roche, Mannheim, Germany) in PBS for
10 min. After blocking with 1% BSA (Cat# 9048468;
Sigma-Aldrich) in PBS for 30 min, cells were subsequently
incubated with Crm1 primary antibodies (1/100 dilution,
Cat# sc-5595-rabbit polyclonal antibody; Santa Cruz
Biotechnology) in blocking buffer for 1 h. After 2 washes
in PBS, cells were incubated with Alexa-Fluor 488-labeled
secondary antibody for 30 min (1/200, Cat# Z25302; Life
Technologies Corp., Carlsbad, CA, USA). After washing,
cells were counterstained with 10 µg/mL diamido-2phenylindole dihydrochloride (DAPI) and coverslips were
mounted with ProLong Gold Antifade Reagent (Cat#
P36934; Life Technologies). Images were visualized using
standard fluorescence microscopy.
2.7. Cell proliferation
The proliferation status of the cells was analyzed using
the xCELLigence Real Time Cell Analyzer System
(RTCA-DP) (Roche) and the (3-(4,5-dimethylthiazol-2yl)- 2,5-diphenyltetrazolium bromide) MTT assay. For
the xCELLigence system proliferation assay, 100 mL of
medium (DMEM) containing 2% FBS was added to the
wells. After 1 h of equilibration with the medium, 100 mL
of cell suspension (1–1.2 × 104 cells/well) was added to
96-well plates. Measurements were collected at an interval
of 15 min and results were analyzed using the RTCA
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software. The monitored cell proliferation was expressed
as percentage cell proliferation.
For the MTT cell proliferation assay, the cells were
cultured separately onto 96-well plates (1–1.2 × 104 cells/
well), 24 h after transfection or inhibition. Briefly, the
cells were incubated with Cell Proliferation Kit I (MTT)
(Cat# 11465007001; Sigma-Aldrich) for 4 h at 37 °C
in a humidified atmosphere of 5% CO2, following the
manufacturer’s instructions. After incubation for 48 h, the
plates were read on a microplate reader (Variscan Flash
Multimode Reader; Thermo Scientific) and the absorbance
of the wells was measured at a wavelength of 595 nm.
2.8. Apoptosis assays
The apoptotic status of cells was investigated using
caspase-activity with the Caspase 3 Activity Assay Kit
(Cat# 12012952001; Roche Life Sciences, Indianapolis,
IN, USA), according to the manufacturer’s instructions.
Shortly, 1–1.2 × 104 cells were plated per well in 96-well
plates and transfected with Crm1-siRNA or treated with
LMB. Caspase activity was measured after 48 h, and
luminescence was monitored using the Veritas Microplate
Luminometer (Turner BioSystems, Sunnyvale, CA, USA).
2.9. Wound‑healing assay
Cells were cultured separately onto 12-well plates in fresh
serum-free DMEM (1–1.2 × 105 cells/well) for 48 h. A
wound was made in the middle of the wells using a sterile
200-µL micropipette tip and photographed using a Leica
inverted microscope after 36 h (Cat# DM1000 DFC 295;
Leica, Frankfurt, Germany), and the images were captured
at 10× magnification.
2.10. Statistical analysis
Data from all the experiments are expressed as means
from a minimum of 3 independent experiments. The
Crm1 expression in HNSCC cell lines was analyzed by
Mann–Whitney test. The rest of the data were statistically
analyzed by Student’s t-test and P < 0.05 was required for
statistical significance.
3. Results
3.1. Crm1 expression in primary and metastatic HNSCC
cell lines
Crm1 expression levels in HNSCC cell lines were
investigated in our study, since it was suggested that the
increased expression of Crm1 was required for various
cellular processes and was associated with the induction of
specific tumorigenic properties (Noske et al., 2008; Yao et
al., 2009; van der Watt et al., 2009, 2014; Shen et al., 2009;
Zhou et al., 2013; Yang et al., 2014; Tai et al., 2014; Liu
et al., 2016). The qRT-PCR analysis showed a significant
increase in Crm1 expression in all of the metastatic
HNSCC cell lines compared to their primary cell lines,
and the highest increase was observed in UT-SCC-74A
and UT-SCC-74B cells (P < 0.05 for all; data not shown).

It was also observed in the metastatic HNSCC cell lines
that a significant increase in the relative Crm1 expression
level was observed compared to the primary cell lines
(approximately 2-fold; Figure 1a).
The Crm1 protein expression level was investigated by
western blot analysis after the detection of the increased
level of mRNA expression of the CRM1 gene in the
HNSCC cell lines. Similar to the qRT-PCR results, the UTSCC-74A and UT-SCC-74B cell lines demonstrated strong
protein expression levels of Crm1 compared to other cell
lines (Figure 1b). The metastatic UT-SCC-16B and UTSCC-60B cells showed higher expression levels of Crm1
compared to their primary counterparts, UT-SCC-16A
and UT-SCC-60A.
To verify the Crm1 protein expression level increase,
the cell lines were also analyzed by immunofluorescence.
When primary and metastatic HNSCC cell lines were
examined, the metastatic cells showed a high level of
Crm1 protein expression as compared to the primary cells
(Figure 1c).
In fluorescent images, Crm1 was mostly localized in the
cytoplasm in primary and metastatic cells, although some
nuclear expression was also detected and was compatible
with the definition of the company producing the antibody
(Figure 1d). Crm1 expression level results were found to
be compatible with each other.
3.2. Crm1 inhibition by LMB decreases HNSCC cell
viability and triggers apoptosis in vitro
In this study, increased levels of the CRM1 gene and
protein expression levels were observed in metastatic
HNSCC cells (Figure 1). We hypothesized that a decrease
in the expression level of Crm1 in HNSCC cells, which
plays a role in the critical intracellular processes underlying
cancerogenesis, could prevent the occurrence of tumoral
physiology. To understand the functional significance of
increased Crm1 expression levels in metastatic HNSCC
cells, we investigated its effect on cells in which its
expression or function was inhibited.
LMB is a specific Crm1 inhibitor that has previously
been used in various studies in cancer cell lines and was
used to inhibit Crm1 function in this study (Wolff et al.,
1997; Kudo et al., 1999; Noske et al., 2008; Tai et al., 2014;
van der Watt et al., 2014). Analysis with the xCELLigence
RTCA-DP system showed that, although there was a
sensitivity to lower doses in the metastatic cell lines, the
highest LMB sensitivity occurred between 10 and 20
nM (P < 0.05, for both primary and metastatic). In the
primary cell lines, the highest sensitivity was observed
at a concentration of 20 nM LMB (P < 0.05; data not
shown). Moreover, metastatic cells are more sensitive to
LMB treatment than primary HNSCC cells (Figure 2a).
In this study, in contrast to the primary cells, the survival
of metastatic head and neck cancer cells was shown to be
closely related to Crm1 function.
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Figure 1. Expression of Crm1 in HNSCC cell lines. (a) Relative Crm1 mRNA expression levels in HNSCC cell lines as determined by
qRT-PCR. Relative mRNA expression levels are significantly upregulated in metastatic HNSCC cells [cancer cell lines (n = 6), P < 0.05]
(scale bar, 200 µm). Results shown are the mean of 6 ± SE. (b) Western blot analysis confirming upregulation of Crm1 in metastatic
HNSCC cells compared to primary cell lines (P < 0.05). Representative bands showing Crm1 protein expression in UT-SCC-74A and
UT-SCC-74B cell lines. β-Actin was used as a control for protein loading. (c) Quantification of Crm1 immunofluorescence in 6 HNSCC
cell lines. Fluorescence was quantified using ZEN software (Carl Zeiss Microscopy GmbH, Jena, Germany). A significant increase in
Crm1 expression in metastatic HNSCC compared to primary cell lines [cancer cell lines (n = 6), P < 0.05]. (d) Immunohistochemical
analysis of Crm1 expression in HNSCC cell lines. Elevated Crm1 expression in metastatic HNSCC compared to primary cancer cells
was observed (P < 0.05). Merged images obtained with anti-Crm1 antibody and DAPI. Representative images showing Crm1 expression
and nuclear staining in UT-SCC-74A and UT-SCC-74B cell lines. Crm1, Chromosome region maintenance 1 protein; DAPI, diamido2-phenylindole dihydrochloride.

Furthermore, the proliferation abilities of LMB-treated
HNSCC cancer cells were analyzed by MTT assay. A
significant increase in the cell death rate was observed in
HNSCC cancer cells treated with LMB. It was observed
that the proliferation ability of metastatic HNSCC cells
treated with LMB was suppressed more than that of the
primary cells (Figure 2b). Additionally, in the caspase-3
assay, caspase-3 activity was observed in HNSCC cells
treated with LMB, and it was also observed that activation
in the metastatic cells was increased about 3-fold more
than in the primary cells. These data revealed that the
functional inhibition of the Crm1 protein activated
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apoptotic pathways, leading to tumor cell death (Figure
2c). Due to the remarkable effects of LMB at doses of 1020 nM on cell death in cancer cells, LMB at 5 nM was used
to show the suppression of migration (Figure 2d). The
migration of HNSCC cells treated with LMB was found
to be decreased by approximately 1.5-fold in primary cell
lines and 1.3-fold in metastatic cell lines (Figure 2e).
3.3. Crm1 knockdown by specific siRNA decreases
HNSCC cell proliferation and induces apoptosis
By using specific siRNA for inhibiting the Crm1 expression
in HNSCC cells, the effect of knockdown on cellular
functions was investigated. HNSCC cancer cells were
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Figure 2. Effect of leptomycin B (LMB) treatment on cell viability, proliferation, and migration. (a) The primary UT-SCC-74A and
metastatic UT-SCC-74B HNSCC cell lines were treated with LMB at increasing nanomolar concentrations and cell viability was assayed
48 h after treatment using the xCELLigence RTCA-DP system. Results shown are the cell index after LMB treatment relative to the
untreated controls. HNSCC cell index in the absence and presence of 20 nM LMB. With LMB treatment metastatic HNSCC cells
were decreased significantly in comparison to the control by using the xCELLigence RTCA-DP system (P < 0.05). (b) Relative cell
proliferation was measured using MTT after 48 h of incubation in the absence or presence of 20 nM LMB. Cell proliferation in LMBtreated HNSCC cells showed a decreased (*P < 0.05, **P < 0.05, ***P < 0.05) (scale bar, 200 µm). (c) Caspase-3 activity in LMB-treated
HNSCC cells. Cells were treated with 20 nM LMB and caspase-3 activity was analyzed as a measure of apoptosis. Caspase-3 activity
in LMB-treated HNSCC cells was increased significantly in comparison to the control (*P < 0.05, **P < 0.05, ***P < 0.05) (scale bar,
200 µm). (d) Wound-healing assay in the absence or presence of 5 nM LMB. Wound-healing assay showing that LMB was effective at
disrupting the migration ability of HNSCC cells (for both P < 0.05) (scale bar, 50 µm). (e) Cell migration in LMB-treated HNSCC cells
showed a decrease (*P < 0.05, **P < 0.05) (scale bar, 200 µm).
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transfected with Crm1-specific siRNA or nontargeting
(NT) control siRNA. The knockdown efficiency was
assessed by qRT-PCR analysis and western blot.
The qRT-PCR analysis showed that Crm1 mRNA levels
were significantly decreased in Crm1-siRNA-transfected
cells compared to the NT control (Figure 3a). Proteins
were harvested 72 h after transfection, and the cell lysates
were analyzed by western blot using anti-Crm1 and antiβ-actin antibodies. Western blot results demonstrated that
the Crm1 protein was significantly suppressed compared
to the nontargeting control in both cell lines (Figure 3b).
To test the inhibitory effect of Crm1 suppression on
HNSCC cell proliferation, a proliferation assay using the
xCELLigence system was performed 48 h after transfection.
Cell index values for each treatment group at 20, 40, 60,
and 120 h were compared. After Crm1 knockdown, the
number of Crm1-siRNA-treated HNSCC cancer cells was
significantly decreased compared to cells treated with the
NT-siRNA (Figure 4a).
In Crm1 knockdown HNSCC cells, the caspase-3
activity was evaluated in order to see whether Crm1
suppression induced apoptosis and reduced the cell

proliferation ability. Compared to the NT control, the
caspase-3 activity in HNSCC cells transfected with Crm1specific siRNA was found to be increased by approximately
0.6-fold in primary cell lines and 2.3-fold in metastatic cell
lines. These results may indicate that inhibiting the CRM1
gene expression triggers cell death in cancer cells (Figure
4b). In addition, the effect of Crm1 knockdown by siRNA
on the migration and wound-healing capacity of HNSCC
cells was investigated and it was observed that Crm1 cell
migration was significantly decreased (Figure 4c). The
migration of HNSCC cells transfected with Crm1-specific
siRNA was found to be decreased by 1.8-fold in primary
cell lines and 2.12-fold in metastatic cell lines (Figure 4d).
4. Discussion
Head and neck cancer is aggressive and highly metastatic,
and the primary treatment option is surgery. Surgical
treatments, due to their outcomes, significantly decrease
the quality of life of the patients (Jemal et al., 2009).
Similarly, due to the high toxicity and the intracellular
drug resistance mechanisms that develop over time for
other available therapeutic options, the 5-year survival rate

Figure 3. Knockdown efficiency of Crm1 in HNSCC cell lines. Crm1-siRNA and
NT-siRNA were transfected in UT-SCC-74A and UT-SCC-74B cells. (a) After 48 h of
transfection, the results showed that Crm1-siRNA compared to the NT-siRNA control
led to a 66.3% decrease for primary HNSCC cells and 86.5% decrease for metastatic
cells in the level of Crm1 mRNA by RT-qPCR (for both P < 0.001) (scale bar, 200 µm).
(b) Western blot analysis demonstrated that Crm1 was suppressed significantly at the
protein level in Crm1-siRNA compared to the NT-siRNA control in HNSCC cells (for
both P < 0.001).
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Figure 4. Effect of inhibiting Crm1 expression on HNSCC cell viability, proliferation, and migration using siRNA. (a) Cell proliferation
assays were performed using the xCELLigence RTCA-DP system. The primary UT-SCC-74A and metastatic UT-SCC-74B HNSCC
cell lines were transfected with siRNA and cell viability was monitored 120 h after transfection. The primary and metastatic HNSCC
cells showed no similar sensitivities to Crm1 inhibition. In primary cells, proliferation decreased by Crm1-siRNA after 80 h (P <
0.05). The metastatic HNSCC cancer cells were significantly reduced by Crm1-siRNA after 20 h (P < 0.05). (b) Caspase-3 activity in
Crm1-knockdown HNSCC cells. Cells were in Crm1-siRNA transfection-activated apoptosis in the HNSCC cells compared to the
nontargeting siRNA‑treated (*P < 0.05, **P < 0.001) (scale bar, 300 µm). (c) In HNSCC cells, there was significant difference between
the Crm1-siRNA- and NT-siRNA-treated cells in terms of migration capability (for both P < 0.05) (scale bar, 50 µm). (e) Cell migration
in Crm1-siRNA-treated HNSCC cells showed a decrease (*P < 0.05, **P < 0.05) (scale bar, 200 µm).

of head and neck cancer is low (Mao et al., 2004; Siegel
et al., 2014). For this reason, there is an urgent need to
investigate the molecular characteristics of head and neck
cancer and to discover new therapeutic target molecules
associated with specific cellular pathways to overcome
these potential drug resistance mechanisms.
Crm1 is very critical for the cell cycle and proliferation,
and it is responsible for the nuclear export of more than
285 critical proteins involved in intracellular processes
(Fukuda et al., 1997; Nguyen et al., 2012; Turner et al.,
2012; Fung et al., 2014). Furthermore, transcription
factors that are the target cargo proteins of Crm1 have
critical roles in the regulation of intracellular processes via
their expression levels and functions, which are regulated
by the cell cycle and signaling proteins (Henderson et
al., 2000; Mariano et al., 2006; Chan et al., 2010; van der
Watt et al., 2011; Brodie et al., 2012; Santiago et al., 2013;
Ishizawa et al., 2015). It has been reported that Crm1 is
expressed in different cell types, its level of expression
changes in various pathologies, and its deregulation may
lead to increased cell proliferation and decreased cell death
(Kudo et al., 1997; Ishizawa et al., 2015).
For the first time, a study was conducted that showed
an increased expression of Crm1 in cancerous tissues, and

the results of this study indicated a possible relationship
between Crm1 and cancer (van der Watt et al., 2009).
Additionally, it was shown in advanced studies that the
increased expression of Crm1 was verified in 17 different
tumor types, including multiple myeloma (Tai et al., 2014),
ovarian cancer (Noske et al., 2008), osteosarcoma (Yao et
al., 2009), esophageal cancer (van der Watt et al., 2014;
Yang et al., 2014), glioma (Shen et al., 2009), gastric cancer
(Zhou et al., 2013), and renal cancer (Liu et al., 2016). This
overexpression was correlated with poor patient survival
and was reported to have a negative prognostic value
(Turner et al., 2011). Therefore, recent studies, especially
on various types of cancer, have brought Crm1 to the
foreground as an important target molecule (Yashiroda et
al., 2003; Turner et al., 2011).
It was also reported that cell cycle inhibitors involved in
the pathogenesis of cancer were targeted by Crm1; tumor
suppressor proteins, including BRAC1, the FOXOs, Rb,
APC, RASSF2, Merlin, nucleophosmin, survivin, STAT,
a κB-α inhibitor (IκB-α), and transcription factors NFY/
CBP, Sp1, and p53, are all affected by Crm1 overexpression
and contribute to cellular transformations together with
Crm1. Crm1 deregulation has been demonstrated mainly
in cervical squamous cell carcinoma (van der Watt et
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al., 2009), though also in many other cancer types, such
as esophageal cancer (van der Watt et al., 2014; Yang et
al., 2014), multiple myeloma (Tai et al., 2014), and renal
cancer (Liu et al., 2016), and it has been shown that
Crm1 inhibition has the potential to target continuously
proliferating cancer cells (Kau et al., 2004). Crm1-targeting
agents containing inhibitors, such as LMB (Newlands et al.,
1996; Wolff et al., 1997; Kudo et al., 1999), N-azolylacrylate
analogs (Daelemans et al., 2002), Valeriana fauriei and
Alpinia galanga l (Tamura et al., 2009), the FOXO family
(Kau et al., 2003), and the novel SINE (Sakakibara et al.,
2011), are highly potent candidate molecules that could
be used to develop anticancer therapies when the role of
Crm1 is confirmed. Today, more data are needed to reveal
the role of Crm1 and its association to cellular pathways in
order to clarify the pathogenesis of HNSCC and to develop
effective treatment strategies.
In the HNSCC cell lines, we detected the expression
of nuclear export protein Crm1, which is a member of the
karyopherin family. We found that Crm1 is increasingly
expressed in metastatic cells compared to primary HNSCC
cells. To our knowledge, this is the first in vitro study
reporting the expression of Crm1 in HNSCC cell lines.
It also supports the idea that Crm1 might play a role in
cancerogenesis since its suppression reduced cell growth
and migration, potentially making it a potent biomarker
in HNSCC diagnostics and treatment (Noske et al., 2008;
Shen et al., 2009; van der Watt et al., 2009, 2014; Yao et al.,
2009; Zhou et al., 2013; Tai et al., 2014; Yang et al., 2014;
Liu et al., 2016). Another important first in our study is
the examination of mRNA and protein expression levels in
primary HNSCC cells and their metastatic cell lines. UTSCC-74A, a primary tumor cell line, and UT-SCC-74B, its
corresponding metastatic tumor cell line, demonstrated
increased mRNA and protein expression levels of Crm1
compared to other cell lines. This difference may be due
to the different phenotypic characteristics in UT-SCC-74A
and -74B cells, such as clinicopathologic classification,
histological grading, and an already high migration and
metastatic capacity related to other acquired genetic
changes (Sheikh Ali et al., 2008; Lange et al., 2009;
Maushagen et al., 2016; Bender et al., 2018).
We have taken 2 approaches to understanding the
functional association between HNSCC cells and Crm1,
which plays a role in the critical intracellular processes
underlying cancerogenesis, and have determined the
potential of Crm1 to be a therapeutic target. In order to
suppress Crm1 gene expression, we used specific siRNA
interference, and to inhibit protein function, we used a
Crm1-targeting drug, LMB. Similar to LMB inhibition,
when the siRNA approach was used, Crm1 expression
levels decreased in the Crm1 knockdown cells and some of
the tumorigenic properties of the HNSCC cells were altered
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via the induction of apoptosis. Additionally, decreases in
cellular proliferation, migration, and the wound-healing
abilities of HNSCC cells were observed.
LMB covalently binds to Crm1-specific cysteine
residues and inhibits Crm1 binding to target cargo
molecules (Wolff et al., 1997; Kudo et al., 1999). In the
study of van der Watt et al. (2009) performed on cervical
cancer cells, it was reported that transformed cells were
more sensitive to LMB treatment than normal cells, and
LMB was highly cytotoxic at nanomolar concentrations.
It is possible that the difference in sensitivity to LMB
was related to the variability in the proliferation and
metabolism of cancerous and normal cells. Kuusisto et
al. (2011) suggested that to sustain the high proliferative
abilities of transformed cancer cells and to maintain their
metabolic activities, these cells required the increased
expression and higher activity of proteins, such as Crm1,
and therefore might be more sensitive to LMB than normal
cells. We presented herein that metastatic cancer cells were
much more susceptible to lower doses of LMB therapy
compared to primary HNSCC cells, and we believe that
the difference in response to Crm1 inhibition is promising
in the development of Crm1-targeted anticancer drugs.
In our study, a significant reduction in the cell growth
rate and migration was observed after Crm1 inhibition
and knockdown in HNSCC cells. Previous studies have
found that MMP2 and MMP9 expression levels are
associated with an increased proliferation and metastatic
ability of HNSCC cells (Kaomongkolgit et al., 2013; Chan
et al., 2016). Recently, it was shown that Crm1 inhibition
in epithelial ovarian carcinoma cells reduced MMP2 and
MMP9 levels and their enzymatic activities, possibly
through mTOR-STAT3 signaling (Shao et al., 2017).
Therefore, in our study, we suggested that Crm1 inhibition
may result in a decrease in the activity of MMP2 and
MMP9 in cells, leading to a decrease in the migration and
wound-healing capacity of HNSCC cells; however, further
functional investigations are needed.
In addition, serine protease 6 (Ser6), associated with
cell death, induces phosphorylated galectin-3 (Gal-3)
to initiate cell cycle arrest and protects the cells from
apoptosis (Yoshii et al., 2002). Crm1 is responsible for the
nuclear export of phosphorylated Ser6-phosphorylatedGal-3, and the overactivity of Crm1 in breast carcinoma
cells causes excessive cytoplasmic accumulation of Gal3, resulting in antiapoptotic activity leading to cancer
progression (Takenaka et al., 2004). However, in one of the
previous studies on HNSCC cells, it was reported that high
levels of Gal-3 in tumor cells led to a cytoplasmic shift,
and these cells developed apoptosis resistance (Saussez
et al., 2008). The observed increase in apoptotic response
following Crm1 inhibition and Crm1 knockdown in this
study could have resulted in the loss of other abnormal
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oncogenic regulatory mechanisms induced by the
increased expression of Crm1, as well as causing a change
in this pathway.
Head and neck carcinomas compose more than 90%
of all squamous cell carcinomas. HNSCC has a high
prevalence of neck metastases before spreading to distant
regions (Easty et al., 1981). Currently, up to 300 HNSCC
cell lines have been established, and according to the
location of the tumor, these are classified into 7 groups.
Most, however, originate from the oral cavity (Lin et al.,
2007). Our study does have some limitations. Although
the cell lines used herein do represent the general
characteristics of head and neck tumors, they may have
different genetic and phenotypic characteristics from other
lines. Therefore, our data need to be confirmed in other
head and neck cancer cell lines. In addition, our in vitro
study has yet to demonstrate that Crm1 plays an important
role in cell proliferation and migration in carcinogenesis,
and despite the theoretical data, in vivo studies revealing
the expression and molecular associations of Crm1 are
still lacking. Our study shows only the effects of Crm1 by
siRNA knockdown on primary and metastatic head and

neck cancer cell lines. For this reason, Crm1 expression
needs to be investigated in one or more normal cell lines
and to be compared in normal and head neck cancer
cells, and also in a clinical setting, including through the
measurement of expression levels in patient plasma as well
as in situ and in migrated tumor specimens to verify its
impact on the prognosis.
In conclusion, this study has demonstrated the
phenotypic effects of Crm1 on head and neck cancer cells,
revealing an ability of this protein to induce proliferation
and migration in these head and neck cancer cells. The
current study opens up the potential use of Crm1 as a
biological marker and a therapeutic target in the diagnosis
and treatment of head and neck cancer. Further studies are
needed to clarify and confirm this potential.
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